{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T21:58:10Z","timestamp":1784152690532,"version":"3.55.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100016387","name":"Grifols","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Convalescent plasma has been used to treat many viral diseases including Ebola. The manufacture of a purified anti-Ebola virus (EBOV) intravenous immunoglobulin (IVIG) from pooled convalescent plasma is described in this paper.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>An enzyme-linked immunosorbent assay (ELISA) targeting an EBOV surface glycoprotein antigen was used to determine the immunoglobulin titer of pooled plasma and purified anti-EBOV IVIG. Anti-EBOV IVIG was also tested in neutralization assays using a vesicular stomatitis virus pseudovirion expressing EBOV glycoprotein on its surface and with live EBOV. Finally, the efficacy of the anti-EBOV IVIG was assessed in a mouse model of EBOV infection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In the ELISA, the anti-EBOV IVIG was shown to have a 7-fold increase in immunoglobulin G (IgG) titer over pooled convalescent plasma. In both the pseudovirion and live virus assays, the anti-EBOV IVIG showed approximately 5- to 6-fold increased potency over pooled plasma. Anti-EBOV IVIG also significantly improved survivability in mice infected with the virus when administered concurrently or 2 days after infection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These data support this purified anti-EBOV IVIG merits additional investigation and clinical trials for treatment and postexposure prophylaxis of Ebola virus disease. The experience gained can be applied to manufacture hyperimmune globulins against other emerging viruses.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiab432","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T14:30:51Z","timestamp":1630074651000},"page":"733-740","source":"Crossref","is-referenced-by-count":4,"title":["Characterization of an Anti-Ebola Virus Hyperimmune Globulin Derived From Convalescent Plasma"],"prefix":"10.1093","volume":"225","author":[{"given":"Jonathan M","family":"Ciencewicki","sequence":"first","affiliation":[{"name":"Grifols Bioscience R&D, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S","family":"Herbert","sequence":"additional","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Storm","sequence":"additional","affiliation":[{"name":"National Emerging Infectious Diseases Laboratories, Boston University School of Medicine, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M","family":"Josleyn","sequence":"additional","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen E","family":"Huie","sequence":"additional","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay G A","family":"McKay","sequence":"additional","affiliation":[{"name":"National Emerging Infectious Diseases Laboratories, Boston University School of Medicine, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Griffiths","sequence":"additional","affiliation":[{"name":"National Emerging Infectious Diseases Laboratories, Boston University School of Medicine, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M","family":"Dye","sequence":"additional","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Willis","sequence":"additional","affiliation":[{"name":"Grifols Bioscience R&D, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Arora","sequence":"additional","affiliation":[{"name":"Grifols Bioscience R&D, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,27]]},"reference":[{"key":"2022021508045659400_CIT0001","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2105\/AJPH.8.10.741","article-title":"The use of convalescent human serum in influenza pneumonia\u2014a preliminary report","volume":"8","author":"McGuire","year":"1918","journal-title":"Am J Public Health (N Y)"},{"key":"2022021508045659400_CIT0002","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1111\/trf.14530","article-title":"Characterization of source plasma from self-identified vaccinated or convalescent donors during the 2009 H1N1 pandemic","volume":"58","author":"Khalenkov","year":"2018","journal-title":"Transfusion"},{"key":"2022021508045659400_CIT0003","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3851\/IMP3243","article-title":"Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience","volume":"23","author":"Ko","year":"2018","journal-title":"Antivir Ther"},{"key":"2022021508045659400_CIT0004","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2022021508045659400_CIT0005","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022021508045659400_CIT0006","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41591-020-1088-9","article-title":"Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study","volume":"26","author":"Liu","year":"2020","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"2022021508045659400_CIT0007","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1086\/514298","article-title":"Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee","volume":"179","author":"Mupapa","year":"1999","journal-title":"J Infect Dis"},{"key":"2022021508045659400_CIT0008","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa1511812","article-title":"Evaluation of convalescent plasma for Ebola virus disease in Guinea","volume":"374","author":"van Griensven","year":"2016","journal-title":"N Engl J Med"},{"key":"2022021508045659400_CIT0009","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/infdis\/jiy199","article-title":"Anti-Ebola virus antibody levels in convalescent plasma and viral load after plasma infusion in patients with Ebola virus disease","volume":"218","author":"Brown","year":"2018","journal-title":"J Infect Dis"},{"key":"2022021508045659400_CIT0010","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/trf.14580","article-title":"Detection, characterization, and enrollment of donors of Ebola convalescent plasma in Sierra Leone","volume":"58","author":"Tedder","year":"2018","journal-title":"Transfusion"},{"key":"2022021508045659400_CIT0011","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/cid\/civ680","article-title":"The use of Ebola convalescent plasma to treat Ebola virus disease in resource-constrained settings: a perspective from the field","volume":"62","author":"van Griensven","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2022021508045659400_CIT0012","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJMsr1904253","article-title":"The ongoing Ebola epidemic in the Democratic Republic of Congo, 2018\u20132019","volume":"381","author":"Ilunga Kalenga","year":"2019","journal-title":"N Engl J Med"},{"key":"2022021508045659400_CIT0013","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"2022021508045659400_CIT0014","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S1473-3099(17)30677-1","article-title":"Ebola virus disease: an update on post-exposure prophylaxis","volume":"18","author":"Fischer","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2022021508045659400_CIT0015","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1046\/j.1423-0410.2003.00285.x","article-title":"Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography","volume":"84","author":"Lebing","year":"2003","journal-title":"Vox Sang"},{"key":"2022021508045659400_CIT0016","author":"Grifols."},{"key":"2022021508045659400_CIT0017","article-title":"WHO collaborative study to assess the suitability of the 1st international standard and the 1st international reference panel for antibodies to Ebola virus","author":"Wilkinson","year":"2017"},{"key":"2022021508045659400_CIT0018","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1128\/JVI.73.7.6024-6030.1999","article-title":"Ebola virus can be effectively neutralized by antibody produced in natural human infection","volume":"73","author":"Maruyama","year":"1999","journal-title":"J Virol"},{"key":"2022021508045659400_CIT0019","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"issue":"Suppl","key":"2022021508045659400_CIT0020","first-page":"59","article-title":"Gamma globulin in the prevention of viral hepatitis. A study on the effect of medium size doses","volume":"36","author":"Kluge","year":"1963","journal-title":"Rev Int Serv Sante Armees"},{"key":"2022021508045659400_CIT0021","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1056\/NEJM199312163292503","article-title":"Liver transplantation in European patients with the hepatitis B surface antigen","volume":"329","author":"Samuel","year":"1993","journal-title":"N Engl J Med"},{"key":"2022021508045659400_CIT0022","first-page":"1","article-title":"Human rabies prevention\u2014United States, 2008: recommendations of the Advisory Committee on Immunization Practices","volume":"57","author":"Manning","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"2022021508045659400_CIT0023","first-page":"63","article-title":"Plasma immunoglobulin concentrations in a West African (Gambian) community and in a group of healthy British adults","volume":"3","author":"Rowe","year":"1968","journal-title":"Clin Exp Immunol"},{"key":"2022021508045659400_CIT0024","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.anai.2020.03.018","article-title":"Immunoglobulin G and immunoglobulin G subclass concentrations differ according to sex and race","volume":"125","author":"Harkness","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2022021508045659400_CIT0025","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2217\/fvl.09.56","article-title":"Ebolavirus glycoprotein structure and mechanism of entry","volume":"4","author":"Lee","year":"2009","journal-title":"Future Virol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiab432\/41851358\/jiab432.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/4\/733\/42508694\/jiab432.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/4\/733\/42508694\/jiab432.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T08:12:28Z","timestamp":1644912748000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/225\/4\/733\/6358615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,27]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,8,27]]},"published-print":{"date-parts":[[2022,2,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiab432","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,2,15]]},"published":{"date-parts":[[2021,8,27]]}}}